1 year 87.14
Extreme 87.14
97.14
3 years 19.8
Extreme 19.805
97.14
5 years 12.03
Extreme 12.03
97.14
10 years 10.18
Extreme 10.18
97.14
Manager TitleAgeSince
Chief Executive Officer 65 2025-12-11
Chief Tech/Sci/R&D Officer 50 2024-06-30
Chief Tech/Sci/R&D Officer 58 2021-04-30
Director TitleAgeSince
Director/Board Member 65 2025-12-11
Director/Board Member 55 2025-12-11
Director/Board Member 48 2025-12-11
Date Insider Type Main position Quantity % Market Cap. Importance
12/26/25 BuyCompany 76,922,983 -
12/22/25 BuyCompany 815,444 1.0751%
12/18/25 BuyCompany 278,441 0.3671%
Change 5-day change 1-year change 3-year change Capi.($)
-7.14%-.--% - - 6.83B
+2.41%+0.29%+39.41%+72.14% 64.69B
-0.15%+7.50%+11.42%+71.27% 54.78B
+0.57%+4.60%+7.71%+90.93% 53.49B
+0.37%+4.67%+26.68%+49.64% 45.98B
-1.21%+2.32%+21.50%+118.33% 42.94B
-0.37%+5.07%+243.23%+789.58% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
+1.19%-4.98%+26.31%-0.76% 23.97B
-0.38%+5.68%+38.39%+28.35% 23.67B
Average -0.47%+2.41%+48.08%+140.89% 42.57B
Weighted average by Cap. +0.26%+2.73%+46.02%+142.84%
Logo Merus N.V.
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
Employees
291
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Merus N.V.
  1. Stock Market
  2. Stocks
  3. MRUS Stock